BRAF V600E-mutated metastatic Wilms tumor with complete response to targeted RAF/MEK inhibition: a post-treatment follow-up case report - Takeaways - MDSpire

BRAF V600E-mutated metastatic Wilms tumor with complete response to targeted RAF/MEK inhibition: a post-treatment follow-up case report

  • By

  • Iliani Slika

  • Carlene K. Edwards

  • Kenneth J. Cohen

  • Alan D. Friedman

  • Christine A. Pratilas

  • Patience Odeniyide

  • May 7, 2026

Share

  • 1

    Wilms tumor is the most common pediatric renal malignancy, with a high overall survival rate for favorable histology cases.

  • 2

    Recurrent Wilms tumor has poor outcomes, and there are no established treatment guidelines for patients with multiple relapses.

  • 3

    A pediatric patient with BRAF V600E mutation achieved complete remission after treatment with BRAF and MEK inhibitors.

  • 4

    The patient remained disease-free for two years after stopping targeted therapy, marking a significant treatment success.

  • 5

    This case highlights the potential of precision-targeted therapy in managing relapsed Wilms tumor with specific genetic mutations.

Original Source(s)

BRAF V600E-mutated metastatic Wilms tumor with complete response to targeted RAF/MEK inhibition: a post-treatment follow-up case report

  • by Iliani Slika, Carlene K. Edwards, Kenneth J. Cohen, Alan D. Friedman, Christine A. Pratilas, Patience Odeniyide

  • May 7, 2026

Related Content

One Pathway for Esophageal Cancer?

Molecular profiling reveals precursor signals in BE-negative esophageal cancer

  • May 7, 2026

  • 2 min
Plasma miR-371a-3p Predicts Recurrence in Stage I Testicular Cancer: Interim Results From the CLIMATE Study

In the management of stage I testicular cancer, a persistent clinical dilemma is the identification of patients who truly need adjuvant treatment after orchiectomy rather than active surveillance alon...

‘Promising’ Signal Only: ctDNA in Early Breast Cancer Not Yet Ready for Clinical Use

Despite compelling prognostic associations across multiple retrospective data sets, no interventional trial has demonstrated that acting on circulating tumor DNA testing results in early breast cancer...